These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 23652861)

  • 21. Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.
    Tomoi Y; Soga Y; Iida O; Fujihara M; Ando K
    J Endovasc Ther; 2017 Oct; 24(5):640-646. PubMed ID: 28675951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial.
    Bosiers M; Deloose K; Callaert J; Verbist J; Hendriks J; Lauwers P; Schroë H; Lansink W; Scheinert D; Schmidt A; Zeller T; Beschorner U; Noory E; Torsello G; Austermann M; Peeters P
    J Endovasc Ther; 2015 Feb; 22(1):1-10. PubMed ID: 25775672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stent placement vs. balloon angioplasty for popliteal artery treatment: two-year results of a prospective, multicenter, randomized trial.
    Rastan A; Krankenberg H; Baumgartner I; Blessing E; Müller-Hülsbeck S; Pilger E; Scheinert D; Lammer J; Beschorner U; Noory E; Neumann FJ; Zeller T
    J Endovasc Ther; 2015 Feb; 22(1):22-7. PubMed ID: 25775675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).
    Matsumura JS; Yamanouchi D; Goldstein JA; Pollock CW; Bosiers M; Schultz GA; Scheinert D; Rocha-Singh KJ
    J Vasc Surg; 2013 Jul; 58(1):73-83.e1. PubMed ID: 23642924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-expanding nitinol stents of high versus low chronic outward force in de novo femoropopliteal occlusive arterial lesions (BIOFLEX-COF trial): study protocol for a randomized controlled trial.
    Wressnegger A; Kaider A; Funovics MA
    Trials; 2017 Dec; 18(1):594. PubMed ID: 29237489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JetStream Rotational and Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries: Results of the JETSTREAM-ISR Feasibility Study.
    Shammas NW; Shammas GA; Banerjee S; Popma JJ; Mohammad A; Jerin M
    J Endovasc Ther; 2016 Apr; 23(2):339-46. PubMed ID: 26921281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
    Tanabe Y; Ito E; Nakagawa I; Suzuki K
    Int J Cardiol; 2001 May; 78(3):285-91. PubMed ID: 11376832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twelve-month experience with the GORE® TIGRIS® Vascular Stent in the superficial femoral and popliteal arteries.
    Piorkowski M; Freitas B; Steiner S; Botsios S; Bausback Y; Scheinert D; Schmidt A
    J Cardiovasc Surg (Torino); 2015 Feb; 56(1):89-95. PubMed ID: 25410147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Cilostazol Following Endovascular Intervention for Peripheral Artery Disease.
    Nanto K; Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Uematsu M
    Angiology; 2015 Sep; 66(8):774-8. PubMed ID: 25228649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of cilostazol on angiographic restenosis after coronary stent placement.
    Park SW; Lee CW; Kim HS; Lee NH; Nah DY; Hong MK; Kim JJ; Park SJ
    Am J Cardiol; 2000 Sep; 86(5):499-503. PubMed ID: 11009265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.
    Koppensteiner R; Spring S; Amann-Vesti BR; Meier T; Pfammatter T; Rousson V; Banyai M; van der Loo B
    J Vasc Surg; 2006 Dec; 44(6):1247-53. PubMed ID: 17145426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classification and clinical impact of restenosis after femoropopliteal stenting.
    Tosaka A; Soga Y; Iida O; Ishihara T; Hirano K; Suzuki K; Yokoi H; Nanto S; Nobuyoshi M
    J Am Coll Cardiol; 2012 Jan; 59(1):16-23. PubMed ID: 22192663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Angiographic Risk Score for Femoropopliteal Interventions.
    Iida O; Takahara M; Soga Y; Fujihara M; Kawasaki D; Hirano K; Choi D; Mano T
    J Endovasc Ther; 2020 Dec; 27(6):967-973. PubMed ID: 32813589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
    Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M
    J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
    Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
    J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis.
    Iida O; Soga Y; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M; Muramatsu T; Inoue N; Nanto S; Uematsu M
    J Endovasc Ther; 2011 Dec; 18(6):753-61. PubMed ID: 22149222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial.
    Tepe G; Laird J; Schneider P; Brodmann M; Krishnan P; Micari A; Metzger C; Scheinert D; Zeller T; Cohen DJ; Snead DB; Alexander B; Landini M; Jaff MR;
    Circulation; 2015 Feb; 131(5):495-502. PubMed ID: 25472980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents.
    Chan YC; Cheng SW; Ting AC; Cheung GC
    J Vasc Surg; 2014 Feb; 59(2):384-91. PubMed ID: 24461862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.